N,N-二烯丙基丙烯酰胺 | 3085-68-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N-二烯丙基丙烯酰胺
• 英文名称: N,N-diallylacrylamide
• 英文别名: N,N-bis(prop-2-enyl)prop-2-enamide
• CAS: 3085-68-5
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: BLYOHBPLFYXHQA-UHFFFAOYSA-N

物化性质

• 沸点：
  108-110°C 3mm
• 密度：
  0.906±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险类别码：
  R20/21/22
• 海关编码：
  2924199090
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  N,N-二烯丙基丙烯酰胺 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 乙二醇甲醚 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ET_A Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722

  摘要：

  We have discovered a novel class of endothelin (ET) receptor antagonists through pharmacophore analysis of the existing non-peptide ET antagonists. On the basis of this analysis, we determined that a pyrrolidine ring might replace the indan ring in SE 209670. The resultant compounds were readily prepared and amenable to extensive SAR studies. Thus a series of N-substituted trans,trans-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl) pyrrolidine-3-carboxylic acids (8) have been synthesized and evaluated for binding at ET(A) and ET(B) receptors. Compounds with N-acyl and simple N-alkyl substituents had weak activity. Compounds with N-alkyl substituents containing ethers, sulfoxides, or sulfones showed increased activity. Much improved activity resulted from compounds where the N-substituents were acetamides. Compound 17u (A-127722) with the N,N-dibutylacetamide substituent is the best of the series. It has an IC50 = 0.36 nM for inhibition of ET-1 radioligand binding at the ETA(A) receptor, with a 1000-fold selectivity for the ET(A) vs the ET(B) receptor. It is also a potent inhibitor (IC50 = 0.16 nM) of phosphoinositol hydrolysis stimulated by ET-1, and it antagonized the ET-l-induced contraction of the rabbit aorta with a pA(2) = 9.20. The compound has 70% oral bioavailability in rats.

  DOI：

  10.1021/jm9505369
• 作为产物：
  描述：

  丙烯酰氯 、 二烯丙基胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N,N-二烯丙基丙烯酰胺
  参考文献：
  名称：

  钾碱催化烯丙醇迈克尔加成到 α,β-不饱和酰胺：范围和机理见解

  摘要：

  我们在此报告了第一次 KHMDS 催化的烯丙醇迈克尔加成反应，通过烯丙基异构化将烯丙醇加成到 α,β-不饱和酰胺。该反应在仅 5 mol% 的 KHMDS 存在下顺利进行，以高产率提供各种 1,5-酮酰胺。包括实验和计算研究在内的机理研究表明，KHMDS 催化通过隧穿辅助的 1,2-氢化物转移从烯丙醇原位生成烯醇化物是这种转化成功的关键。

  DOI：

  10.1002/adsc.202100272

文献信息

• Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
  申请人：——

  公开号：US20030129247A1

  公开（公告）日：2003-07-10

  There are provided thermotropic liquid crystal polymer microcapsules which can show behavior of liquid crystal as it is within polymer phase due to phase separation between liquid crystal and polymer, so to be incorporated into cosmetic composition as an additive for visual effect, and in loading active ingredients within liquid crystal, can improve the stability of the active ingredients in cosmetic base; and a method for preparing the same; and cosmetic compositions containing the same.

  提供了热致液晶聚合物微胶囊，由于液晶与聚合物之间的相分离，这些微胶囊可以展现液晶在聚合物相中的行为，因此可以作为化妆品组合物中的添加剂用于视觉效果，并且在液晶中装载活性成分，可以提高这些活性成分在化妆品基料中的稳定性；以及制备这些微胶囊的方法；以及含有这些微胶囊的化妆品组合物。
• Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135385A1

  公开（公告）日：2007-06-14

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

  吲哚和与吲哚相关的化合物、组合物以及方法被披露。发明中的这些化合物作为磷脂酶抑制剂非常有用。发明中的这些化合物和组合物用于治疗动物受试者中的磷脂酶相关状况，例如胰岛素相关、体重相关和/或胆固醇相关状况。
• [EN] INHIBITORS OF NHE-MEDIATED ANTIPORT<br/>[FR] INHIBITEURS D'ANTIPORT À MÉDIATION PAR NHE
  申请人：ARDELYX INC

  公开号：WO2018129557A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds (Ι') and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (Ι') and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (Ι') and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物(Ι')及其在治疗与液体潴留或盐超负荷相关的疾病的方法中的用途，例如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病以及过氧化物酶体增殖物激活受体（PPAR）gamma激动剂引起的液体潴留。本公开还涉及化合物(Ι')及其在治疗高血压的方法中的用途。本公开还涉及化合物(Ι')及其在治疗胃肠道疾病的方法中的用途，包括治疗或减少与胃肠道疾病相关的疼痛。
• Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix
  申请人：American Cyanamid Company

  公开号：US05929097A1

  公开（公告）日：1999-07-27

  The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by the formula ##STR1## where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A.

  本发明涉及新发现的低分子量、非肽类基质金属蛋白酶（例如明胶酶、溶基质素和胶原酶）和肿瘤坏死因子α转化酶（TACE，肿瘤坏死因子α转化酶）的抑制剂，这些抑制剂用于治疗与这些酶相关的疾病，如关节炎、肿瘤生长和转移、血管生成、组织溃疡、异常伤口愈合、牙周病、骨病、蛋白尿、动脉瘤性主动脉疾病、关节创伤后的退行性软骨损失、神经系统脱髓鞘疾病、移植物排斥、恶病质、厌食、炎症、发热、胰岛素抵抗、感染性休克、充血性心力衰竭、中枢神经系统炎症性疾病、炎症性肠病、HIV感染、与年龄相关的黄斑变性、糖尿病视网膜病变、增生性玻璃体视网膜病变、早产儿视网膜病变、眼内炎症、圆锥角膜、干燥综合症、近视、眼内肿瘤、眼内血管生成/新生血管。本发明的TACE和MMP抑制的邻磺酰胺基芳基羟肟酸由下式表示：##STR1##，其中羟肟酸基团和磺酰胺基团通过相邻的碳原子与A组连接。
• Additives for inhibiting the formation of gas hydrates
  申请人：——

  公开号：US20040030206A1

  公开（公告）日：2004-02-12

  The invention relates to the use of polymers which contain between 1 and 99 mol-% structural units of formula 1, 1 wherein R 1 represents hydrogen or C 1 -C 6 alkyl, R 2 represents C 1 -C 24 -alkyl, C 2 -C 24 -alkylene or a C 6 -C 18 -aryl radical, which can be substituted with a C 1 -C, 12 -alkyl group, A represents identical or different C 2 -C 4 alkylene radicals and, x, represents whole number from 2-40 in quantities from 0.01-2 wt-%, in quantities from 0.01 to 2 wt-%, in relation to the aqueous phase. Said The polymers can be used as gas hydrate inhibitors.

  该发明涉及使用聚合物，其中包含1至99摩尔％的结构单元，其化学式为1， 1 其中R 1 代表氢或C 1 -C 6 烷基，R 2 代表C 1 -C 24 -烷基，C 2 -C 24 -亚烷基或C 6 -C 18 -芳基，可用C 1 -C 12 -烷基基团取代，A代表相同或不同的C 2 -C 4 亚烷基基团，x代表2-40的整数，其含量为0.01-2重量％，相对于水相。所述聚合物可用作天然气水合物抑制剂。